Literature DB >> 16487959

Heterologous desensitization is evoked by both agonist and antagonist stimulation of the human 5-HT(7) serotonin receptor.

Kurt A Krobert1, Kjetil Wessel Andressen, Finn Olav Levy.   

Abstract

Previously, we demonstrated that human serotonin (5-HT) 5-HT(7) receptors display marked constitutive activity. Here, we tested if the constitutive activation of adenylyl cyclase by 5-HT(7) receptors influenced both the desensitization properties of transfected 5-HT(7) receptors and the ability of endogenous G(s)-coupled receptors to activate adenylyl cyclase. Using membranes from stably transfected HEK293 cells expressing the recombinant human 5-HT(7) receptor splice variants (5-HT(7(a)), 5-HT(7(b)) and 5-HT(7(d))), we compared the effects of 1-h or 24-h preincubation of the agonist 5-HT, partial inverse agonists mesulergine and SB269970, and full inverse agonists clozapine and methiothepin on subsequent activation of adenylyl cyclase by both 5-HT through transfected 5-HT(7) receptors and the endogenous G(s)-coupled beta-adrenoceptors and prostaglandin receptors of HEK293 cells. The data show that stable expression of 5-HT(7) receptors is sufficient to attenuate adenylyl cyclase activation by endogenous G(s)-coupled receptors. Interestingly, preincubation with inverse agonists not only failed to result in the predicted resensitization of all receptor mediated adenylyl cyclase activation, but some inverse agonists further attenuated (desensitized) beta-adrenoceptor and prostaglandin-stimulated adenylyl cyclase activation similar to long-term agonist exposure by 5-HT. These effects were not correlated with inverse agonist efficacy, were not accompanied by receptor down-regulation and appear to be mediated by a protein kinase A (PKA) independent mechanism. It is concluded that the human 5-HT(7) receptor mediates heterologous desensitization of endogenous G(s)-coupled receptors through an unknown and potentially novel mechanism.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16487959     DOI: 10.1016/j.ejphar.2005.11.039

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  12 in total

Review 1.  Serotonin 5-HT7 receptor agents: Structure-activity relationships and potential therapeutic applications in central nervous system disorders.

Authors:  Marcello Leopoldo; Enza Lacivita; Francesco Berardi; Roberto Perrone; Peter B Hedlund
Journal:  Pharmacol Ther       Date:  2010-10-20       Impact factor: 12.310

2.  Serotonergic Drugs Inhibit Chikungunya Virus Infection at Different Stages of the Cell Entry Pathway.

Authors:  Ellen M Bouma; Denise P I van de Pol; Ilson D Sanders; Izabela A Rodenhuis-Zybert; Jolanda M Smit
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

Review 3.  5-hydroxtryptamine receptors in systemic hypertension: an arterial focus.

Authors:  Stephanie W Watts; Robert Patrick Davis
Journal:  Cardiovasc Ther       Date:  2011-02       Impact factor: 3.023

4.  Complete AV-block secondary to lithium-clozapine therapy and relapsing multiple sclerosis in a bipolar patient.

Authors:  Edward E E Gabeler; Addy J M van Miltenburg
Journal:  BMJ Case Rep       Date:  2011-12-01

Review 5.  The serotonin 5-HT7 receptors: two decades of research.

Authors:  Evelien Gellynck; Karen Heyninck; Kjetil W Andressen; Guy Haegeman; Finn Olav Levy; Peter Vanhoenacker; Kathleen Van Craenenbroeck
Journal:  Exp Brain Res       Date:  2013-09-17       Impact factor: 1.972

6.  Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists.

Authors:  Jessica A Knight; Carol Smith; Nicole Toohey; Michael T Klein; Milt Teitler
Journal:  Mol Pharmacol       Date:  2008-11-07       Impact factor: 4.436

7.  Mechanisms regulating ApTrkl, a Trk-like receptor in Aplysia sensory neurons.

Authors:  Ikue Nagakura; Jake Ormond; Wayne S Sossin
Journal:  J Neurosci Res       Date:  2008-10       Impact factor: 4.164

8.  Human 5-HT7 receptor-induced inactivation of forskolin-stimulated adenylate cyclase by risperidone, 9-OH-risperidone and other "inactivating antagonists".

Authors:  Nicole Toohey; Michael T Klein; Jessica Knight; Carol Smith; Milt Teitler
Journal:  Mol Pharmacol       Date:  2009-06-09       Impact factor: 4.436

Review 9.  Targeting the Serotonin 5-HT7 Receptor in the Search for Treatments for CNS Disorders: Rationale and Progress to Date.

Authors:  Agnieszka Nikiforuk
Journal:  CNS Drugs       Date:  2015-04       Impact factor: 5.749

10.  Human 5-HT(4) and 5-HT(7) receptor splice variants: are they important?

Authors:  Ian M Coupar; Paul V Desmond; Helen R Irving
Journal:  Curr Neuropharmacol       Date:  2007-12       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.